<DOC>
	<DOC>NCT00130884</DOC>
	<brief_summary>The study will investigate the efficacy of oral levosimendan in patients with chronic New York Heart Association (NYHA) IIIb-IV heart failure (HF) using a composite end-point evaluating patient symptoms, morbidity and mortality. The patients are on treatment for at least 6 months.</brief_summary>
	<brief_title>Peroral Levosimendan in Chronic Heart Failure</brief_title>
	<detailed_description>The patients are randomised to 3 groups; higher or lower levosimendan dose group or placebo.</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Simendan</mesh_term>
	<criteria>Diagnosed chronic heart failure Severe symptoms (NYHA IIIbIV) Optimal ongoing oral treatment for HF Left ventricular ejection fraction less than or equal to 30% Severe obstruction of ventricular outflow tracts Acute myocardial infarction within 30 days before screening Cardiac surgery or coronary angioplasty within 30 days before screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>levosimendan</keyword>
	<keyword>chronic heart failure</keyword>
	<keyword>oral administration</keyword>
</DOC>